Recruiting

Pergolide

Sponsor:

Bronx VA Medical Center

Code:

NCT00252044

Conditions

Schizotypal Personality Disorder

Other Personality Disorders

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Pergolide

Study Details

Brief summary:

Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1) working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis by drug administration of 0.3 mg of oral pergolide interaction for performance on the cognitive tasks, with the schizotypal personality disorder group demonstrating significantly improved peformance compared to the other personality disorder group after pergolide compared with placebo.

Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed by pergolide for four weeks.

Conditions

Schizotypal Personality Disorder

Other Personality Disorders

Study ID

NCT00252044

Start date

Oct, 2000

Status verified date

Nov, 2005

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Inclusion Criteria: DSM-IV criteria for Schizotypal Personality Disorder (or meets full criteria bar one) or another personality disorder and shows impairment on markers of cognitive functioning. Medically healthy, not abusing drugs or alcohol, is at least two weeks medication-free and does not have significant neurological disease.

-

Exclusion Criteria: DSM-IV or RDC criteria for Schizophrenia or any Schizophrenia-related psychotic disorder or for Bipolar Disorder. Any other Axis I disorders must be transient and preceded by the personality disorder diagnosis, which should be primarily responsible for subject's functional impairment.

-

Study Design

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Diagnostic

Interventions and Outcome Measures

Interventions

Pergolide

Primary outcome measure

  • Performance on tests of sustained attention, episodic memory and working memory at baseline and after 2, 4, 6 and 8 weeks on the study medication [ Time Frame: undefined ]

Central Contacts and Locations

Central contacts

Emily Hart

212-241-0441mpgroup@mssm.edu

Locations

Mount Sinai School of Medicine

Recruiting

New York, New York, United States, 10029

More Information

Sponsor

Bronx VA Medical Center

Last update posted

Nov 21, 2005

Last verified

Nov, 2005

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Bronx VA Medical Center on 2005-11-21.